NEW YORK (GenomeWeb) – Researchers have published a new study on BiorXiv in which they combined CRISPR/Cas9 screening with single-cell transcriptome sequencing to combine the benefits of both pooled and arrayed screens.

Led by first author Paul Datlinger and senior author Christoph Bock, researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences described how they combined targeted genome editing and droplet-based RNA-seq to dissect T cell signaling pathways.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.